

CONSOLIDATED			STANDALONE		
Quarter Ended on 30 th June 2011	Year Ended on 31 st March 2011		Particulars	Quarter Ended on 30 th June 2011	Year Ended on 31 st March 2011
(Reviewed)	(Audited)			(Reviewed)	(Audited)
		1	(a) Net Sales / Income from Operations		
20723	78805		Domestic	20723	78805
13749	41859		Exports	11551	38147
34472	120664		Total	32274	116952
145	766		Less : Excise Duty	145	766
34327	119898		Net Sales / Income from Operations	32129	116186
40	306		(b) Other Operating Income	40	306
<b>34367</b>	<b>120204</b>		<b>Total Income</b>	<b>32169</b>	<b>116492</b>
		2	Expenditure		
-1174	-472		(a) Decrease/(increase) in stock in trade and work in progress	-1174	-472
11802	43494		(b) Consumption of Raw Materials & Packing Materials	11802	43494
6545	16018		(c) Purchase of traded goods	4556	12857
3945	14149		(d) Employees' Cost	3945	14149
1209	4714		(e) Research and Development Expense	1209	4714
-8	664		(f) Excise Duty	-8	664
7013	25612		(g) Other Expenditure	6909	25513
<b>29332</b>	<b>104179</b>		<b>Total</b>	<b>27239</b>	<b>100919</b>
5035	16025	3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	4930	15573
8	8	4	Other Income	8	8
5043	16033	5	Profit/(Loss) before Interest, Depreciation, & Exceptional Items	4938	15581
819	2959	6	Depreciation	819	2959
677	2389	7	Interest (Net)	677	2389
3547	10685	8	Profit/(Loss) after Interest but before Exceptional Items	3442	10233
0	0	9	Exceptional Items	0	0
3547	10685	10	Net Profit / (Loss) from Ordinary Activities before Tax	3442	10233
		11	Tax Expense		
723	1864		Less : Provision for Current Tax	711	1801
68	282		(Less)/Add : Provision for Deferred Tax (Liability)/Assets	68	282
2756	8539	12	Net Profit / (Loss) from Ordinary Activities after Tax	2663	8150
3770	3770	13	Paid up Equity Share Capital ( Face value of share Rs 2/- )	3770	3770
-	25758	14	Reserves excluding Revaluation Reserve	-	23851
-	2333	15	Debenture Redemption Reserve	-	2333
1.46	4.53	16	Basic & Diluted EPS (Not Annualised)	1.41	4.32
-	0.86	17	Debt Equity Ratio	-	0.81
-	2.76	18	Debt Service Coverage Ratio	-	2.68
-	9.96	19	Interest Service Coverage Ratio	-	9.66
		20	Public Shareholding		
48763089	48763089		- Number of Shares	48763089	48763089
25.87	25.87		- Percentage of Shareholding	25.87	25.87
		21	Promoters and Promoter Group Shareholding		
		(a)	Pledged / Encumbered		
-	-		Number of Shares	-	-
-	-		Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-
-	-		Percentage of Shares (as a % of the total share capital of the Company)	-	-
		(b)	Non - Encumbered		
139752825	139752825		Number of Shares	139752825	139752825
100.00	100.00		Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00
74.13	74.13		Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13

**Notes :**

1 The above results, which includes unaudited results of the Subsidiary, have been duly reviewed by Statutory Auditors were recommended by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website viz [www.alembic-india.com](http://www.alembic-india.com).

2 This being the first quarter of the Company after the demerger becoming effective on 1st April, 2011, the comparable figures for the corresponding quarter of the previous financial year are not available and not given. However, the sales figures of the pharmaceuticals undertaking for the quarter of the previous final year are as under:

Particulars	(Rs.in Lacs)	
	For the quarter ended on 30.06.11	For the quarter ended on 30.06.10
Sales	34472	25662

3 The Company has made listing application with the Bombay Stock Exchange Limited (BSE) and the National Stock Exchange of India Limited (NSE). Both BSE and NSE have given listing permission vide letter dated 16th May, 2011 and 31st May, 2011 respectively. SEBI Permission for relaxation under rule 19 (2) (b) of Securities Contract (Regulation) Act, 1956 is awaited. On receipt of the said permission from SEBI, BSE and NSE will give trading permission.

4 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).

5 Details of Investor's Complaints for the quarter ended on 30th June, 2011 : Unresolved at the beginning of the quarter-NIL Received during the quarter-NIL, Disposed off during the quarter-NIL, Unresolved at the end of the quarter - Nil

**For Alembic Pharmaceuticals Limited**

Place : Vadodara  
Date : 26th July, 2011

**Chirayu Amin**  
**Chairman and Managing Director**

Visit us at [www.alembic-india.com](http://www.alembic-india.com)